Erste Group Bank Has Weak Outlook for AbbVie FY2027 Earnings

AbbVie Inc. (NYSE:ABBV) – Analysts at Erste Group Bank decreased their FY2027 earnings per share estimates for shares of AbbVie in a report issued on Thursday, June 25th. Erste Group Bank analyst H. Engel now expects that the company will post earnings of $16.21 per share for the year, down from their prior forecast of $16.25. The consensus estimate for AbbVie’s current full-year earnings is $14.28 per share.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.59 by $0.06. The business had revenue of $15 billion for the quarter, compared to analysts’ expectations of $14.72 billion. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The company’s revenue for the quarter was up 12.4% on a year-over-year basis. During the same period in the prior year, the firm earned $2.46 EPS.

Several other research firms have also commented on ABBV. Weiss Ratings reiterated a “hold (c)” rating on shares of AbbVie in a research report on Monday, June 8th. Morgan Stanley boosted their target price on shares of AbbVie from $270.00 to $278.00 and gave the stock an “overweight” rating in a report on Thursday, April 30th. Sanford C. Bernstein restated a “market perform” rating on shares of AbbVie in a research report on Tuesday, June 23rd. Bank of America raised shares of AbbVie from a “neutral” rating to a “buy” rating and set a $234.00 price target for the company in a report on Thursday, April 30th. Finally, Wall Street Zen upgraded AbbVie from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Three analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $253.81.

AbbVie Stock Performance

Shares of ABBV opened at $251.45 on Wednesday. The company’s fifty day moving average is $216.92 and its 200 day moving average is $219.56. AbbVie has a fifty-two week low of $184.38 and a fifty-two week high of $255.99. The stock has a market capitalization of $444.26 billion, a PE ratio of 123.87, a P/E/G ratio of 0.78 and a beta of 0.32.

Institutional Investors Weigh In On AbbVie

Several hedge funds and other institutional investors have recently made changes to their positions in ABBV. Chelsea Counsel Co. bought a new position in AbbVie during the 3rd quarter valued at about $26,000. Litman Gregory Wealth Management LLC bought a new stake in AbbVie in the fourth quarter worth about $28,000. Westend Capital Management LLC bought a new stake in AbbVie in the fourth quarter worth about $29,000. Imprint Wealth LLC boosted its position in shares of AbbVie by 56.2% during the fourth quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock valued at $29,000 after buying an additional 45 shares during the period. Finally, Texas Capital Bancshares Inc TX purchased a new position in shares of AbbVie during the third quarter valued at approximately $31,000. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th will be given a dividend of $1.73 per share. The ex-dividend date is Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a yield of 2.8%. AbbVie’s payout ratio is 340.89%.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie and Genmab reported positive Phase 3 results for Epkinly/epcoritamab in relapsed or refractory diffuse large B-cell lymphoma, with the trial meeting its primary endpoint and suggesting a potential label expansion. Article Title
• Positive Sentiment: AbbVie received positive CHMP opinions in Europe for Rinvoq in severe alopecia areata and non-segmental vitiligo, which could broaden the drug’s addressable market and add future sales momentum if approved. Article Title
• Positive Sentiment: AbbVie’s newly announced $10.9 billion Apogee acquisition and other partnership milestones underscore management’s willingness to invest heavily in future growth and deepen its immunology and neurology pipeline. Article Title
• Neutral Sentiment: Analysts slightly trimmed FY2026 earnings estimates, but the revised forecast remains close to consensus, so this looks like a modest rather than a major headwind. Article Title
• Negative Sentiment: U.S. lawmakers opened an investigation into AbbVie’s clinical trials in China, citing possible national security, ethical, and data-protection concerns. Article Title

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.